KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non Operating Income (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Non Operating Income for 18 consecutive years, with $201.2 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 37.52% year-over-year to $201.2 million; the TTM value through Mar 2026 reached $1.6 billion, up 39.0%, while the annual FY2025 figure was $1.7 billion, 114.98% up from the prior year.
  • Non Operating Income hit $201.2 million in Q1 2026 for Regeneron Pharmaceuticals, up from $176.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $736.5 million in Q3 2025 and bottomed at -$197.4 million in Q1 2022.
  • Average Non Operating Income over 5 years is $172.4 million, with a median of $176.0 million recorded in 2025.
  • Year-over-year, Non Operating Income crashed 227.44% in 2022 and then skyrocketed 156850.0% in 2024.
  • Regeneron Pharmaceuticals' Non Operating Income stood at $237.3 million in 2022, then crashed by 49.43% to $120.0 million in 2023, then tumbled by 164.0% to -$76.8 million in 2024, then skyrocketed by 329.17% to $176.0 million in 2025, then grew by 14.32% to $201.2 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $201.2 million, $176.0 million, and $736.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.